v3.25.1
Note 6 - Accrued Expenses and Other Liabilities - Current (Tables)
3 Months Ended
Mar. 31, 2025
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
  

March 31, 2025

  

December 31, 2024

 

Accrued interest expense

 $437,589  $353,280 

Accrued payroll costs

  825,891   951,247 

Accrued incentive compensation

  431,250   1,031,250 

Accrued vendor liabilities

  453,574   516,804 

Payable to research and development company - current

  831,986   528,878 

LINICO acquisition-related payable

  50,000   1,018,853 

Other accrued expenses

  371,261   118,185 

Total accrued expenses

 $3,401,551  $4,518,497 
Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits by Title of Individual and Type of Deferred Compensation [Table Text Block]
  

As of December 31, 2024

  

Expensed

  

Award Cancelled

  

As of March 31, 2025

 

Executive incentive accrual - 2024

 $1,031,250  $-  $600,000  $431,250 

Total executive incentive accrual

 $1,031,250  $-  $600,000  $431,250 
  

As of December 31, 2023

  

Expensed

  

Award Cancelled

  

As of March 31, 2024

 

Executive incentive accrual - 2023

 $1,332,169  $-  $-  $1,332,169 

Executive incentive accrual - 2024

  -   309,375   -   309,375 

Total executive incentive accrual

 $1,332,169  $309,375  $-  $1,641,544